Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 is the first highly potent and selective Kv1.3 blocker ...

MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...

Functional vision improvements are reported, with optimal pupil size considerations for varying light conditions being ...

Ensifentrine significantly improved lung function after 12 weeks in patients with moderate to severe COPD with and without ...

The company is dropping its social anxiety disorder program but will still test the molecule in post-traumatic stress ...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the best small cap stocks with the highest upside. Barclays initiated ...

Grisso, a microbial science company, today announced the launch of its clinically-validated, precision probiotic product line, entering a market increasingly defined by consumer skepticism and demand ...

Discover how kiwifruit’s unique blend of fiber, vitamin C, and actinidin supports gut function, strengthens immunity, and ...

Learn how accelerating drug discovery is reshaping the pathway from lab findings to effective therapies with real-world data.

Invikafusp alfa demonstrated significant antitumor activity in TMB-H and MSI-H tumors resistant to immune checkpoint blockade, with ORRs ranging from 20.5% to 33.3%. The trial's safety profile was ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown ...